Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase

[1]  J. Seo,et al.  A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response , 2022, Oncogene.

[2]  R. Taboła,et al.  MMP9: A Tough Target for Targeted Therapy for Cancer , 2022, Cancers.

[3]  B. Alghamdi,et al.  Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach , 2022, Life.

[4]  P. Foden,et al.  FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity , 2021, NPJ breast cancer.

[5]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[6]  Jenny C. Chang,et al.  Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2 , 2020, Molecular Cancer Therapeutics.

[7]  Miao Deng,et al.  Prognostic and clinical significance of focal adhesion kinase expression in breast cancer: A systematic review and meta-analysis , 2020, Translational oncology.

[8]  E. Nice,et al.  Overcoming cancer therapeutic bottleneck by drug repurposing , 2020, Signal Transduction and Targeted Therapy.

[9]  Jinsol Yang,et al.  GalaxySagittarius: Structure- and Similarity-Based Prediction of Protein Targets for Druglike Compounds , 2020, J. Chem. Inf. Model..

[10]  G. González-Ávila,et al.  Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. , 2019, Critical reviews in oncology/hematology.

[11]  I. Waizenegger,et al.  The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer , 2018, Oncogenesis.

[12]  Ji Young Kim,et al.  Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition , 2018, International Journal of Cancer.

[13]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[14]  J. Stenvang,et al.  Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment , 2016, EBioMedicine.

[15]  Sriganesh Srihari,et al.  Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. , 2015, Trends in pharmacological sciences.

[16]  J. Quigley,et al.  Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[17]  L. Castellano,et al.  Mammosphere formation assay from human breast cancer tissues and cell lines. , 2015, Journal of visualized experiments : JoVE.

[18]  D. Schlaepfer,et al.  FAK in cancer: mechanistic findings and clinical applications , 2014, Nature Reviews Cancer.

[19]  A. McCluskey,et al.  In Silico Docking, Molecular Dynamics and Binding Energy Insights into the Bolinaquinone-Clathrin Terminal Domain Binding Site , 2014, Molecules.

[20]  W. Coleman,et al.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. , 2013, The American journal of pathology.

[21]  M. Wicha,et al.  Distinct FAK activities determine progenitor and mammary stem cell characteristics. , 2013, Cancer research.

[22]  Ming Li,et al.  The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.

[23]  D. Roberts.  A Preclinical Overview of Ebastine , 2012, Drugs.

[24]  W. Gerald,et al.  Stat3 Mediates Expression of Autotaxin in Breast Cancer , 2011, PloS one.

[25]  André F. Vieira,et al.  Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.

[26]  F. Portillo,et al.  Transcriptional regulation of cell polarity in EMT and cancer , 2008, Oncogene.

[27]  J. Sastre.  Ebastine in allergic rhinitis and chronic idiopathic urticaria , 2008, Allergy.

[28]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[29]  Hwai-Shi Wang,et al.  CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. , 2007, International journal of oncology.

[30]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[31]  Xinming Cai,et al.  Structural Basis for the Autoinhibition of Focal Adhesion Kinase , 2007, Cell.

[32]  R. Preston,et al.  Pharmacokinetics and Safety of Ebastine in Healthy Subjects and Patients with Renal Impairment , 2007, Clinical Pharmacokinetics.

[33]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[34]  N. Carragher,et al.  Src-Mediated Phosphorylation of Focal Adhesion Kinase Couples Actin and Adhesion Dynamics to Survival Signaling , 2004, Molecular and Cellular Biology.

[35]  S. Waldman,et al.  Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers , 2004, Clinical pharmacokinetics.

[36]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Roberts.  A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist. , 1996, Drugs.